BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights Pharmaceutical Investing
Medtronic to announce financial results for its first quarter of fiscal year 2023 Medical Device Investing
Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia Pharmaceutical Investing
Optimi Health Unveils Canada's First Natural Therapeutic Psilocybin Product For Approved Patients Psychedelics Investing
Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy Pharmaceutical Investing
Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma Pharmaceutical Investing
Johnson & Johnson to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference Pharmaceutical Investing
Gilead Sciences and a Coalition of LGBTQ+ and Human Rights-Focused Organizations Mobilize to Address Monkeypox Public Health Emergency Pharmaceutical Investing
The Gummy Project Announces That Its Gummies Land on North America's Largest Passenger Ferry Line Life Science Investing
CORRECTING and REPLACING Cybin Announces Up to USD$35 Million At-The-Market Equity Program Life Science Investing
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
